BIEL + Electrome: The Math Behind the 3,700 Pharmacy Store Rollout
Everyone is tracking Electrome’s active VA deployments, but the massive catalyst hitting the ledger in late 2026 is the 3,700-store national pharmacy retail rollout.
In medical device plays, retail rollouts follow a specific revenue pattern: Pipeline Fill - Restock Velocity. Because Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside, the numbers scale rapidly. Based on a fixed OEM wholesale price of $15.00 per module to BIEL, here is how the math breaks down:
Phase 1: The "Pipeline Fill" (Late 2026)
Before a single consumer buys a product, pharmacies must stock their shelves. This triggers immediate bulk hardware orders for BIEL to fill the retail pipeline.
Initial Shelf Stocking: Estimated 5 to 10 units per store to secure initial shelf presence and display inventory.
Total Initial Hardware Volume: 18,500 to 37,000 upfront units required across all 3,700 locations.
Fixed OEM Price to BIEL: $15.00 per module.
Projected Late-2026 Revenue Catalyst: $277,500 to $555,000 in immediate, upfront OEM hardware invoices.
Phase 2: Sustained Restock Velocity (Full-Year 2027)
The real inflection point happens in 2027 as consumer adoption drives recurring, predictable reorders to keep shelves stocked.
Conservative Turn Rate: Estimated sales of just 2 to 4 units per store, per month.
Annualized Volume Required: 88,800 to 177,600 total units flowing through the network.
Fixed OEM Price to BIEL: $15.00 per module.
Projected 2027 Revenue Run-Rate: $1.33M to $2.66M from the retail channel alone.
The Razor-Blade Advantage: Because Electrome’s platform utilizes BIEL’s core tech (ActiPatch/RecoveryRx), BIEL captures revenue on both the initial kit buy and the high-margin replacement modules consumers purchase later.
Conclusion
Stacked Revenue Streams: This $1.33M–$2.66M retail runway sits on top of the $0.75M–$2.25M baseline revenue BIEL is already modeling for early 2026 from active VA deployments, pilot clinics, and clinical onboarding.
De-Risked Growth: BIEL isn't paying for the retail marketing, distribution logistics, or shelf-space slotting fees—Electrome is. BIEL simply collects clean OEM hardware revenue on every single unit shipped.
Bottom Line: The revenue clock hasn't just started; it is accelerating. Late 2026 establishes the retail footprint, and 2027 is positioned to be a major breakout year for BIEL’s balance sheet.
Everyone is tracking Electrome’s active VA deployments, but the massive catalyst hitting the ledger in late 2026 is the 3,700-store national pharmacy retail rollout.
In medical device plays, retail rollouts follow a specific revenue pattern: Pipeline Fill - Restock Velocity. Because Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside, the numbers scale rapidly. Based on a fixed OEM wholesale price of $15.00 per module to BIEL, here is how the math breaks down:
Phase 1: The "Pipeline Fill" (Late 2026)
Before a single consumer buys a product, pharmacies must stock their shelves. This triggers immediate bulk hardware orders for BIEL to fill the retail pipeline.
Initial Shelf Stocking: Estimated 5 to 10 units per store to secure initial shelf presence and display inventory.
Total Initial Hardware Volume: 18,500 to 37,000 upfront units required across all 3,700 locations.
Fixed OEM Price to BIEL: $15.00 per module.
Projected Late-2026 Revenue Catalyst: $277,500 to $555,000 in immediate, upfront OEM hardware invoices.
Phase 2: Sustained Restock Velocity (Full-Year 2027)
The real inflection point happens in 2027 as consumer adoption drives recurring, predictable reorders to keep shelves stocked.
Conservative Turn Rate: Estimated sales of just 2 to 4 units per store, per month.
Annualized Volume Required: 88,800 to 177,600 total units flowing through the network.
Fixed OEM Price to BIEL: $15.00 per module.
Projected 2027 Revenue Run-Rate: $1.33M to $2.66M from the retail channel alone.
The Razor-Blade Advantage: Because Electrome’s platform utilizes BIEL’s core tech (ActiPatch/RecoveryRx), BIEL captures revenue on both the initial kit buy and the high-margin replacement modules consumers purchase later.
Conclusion
Stacked Revenue Streams: This $1.33M–$2.66M retail runway sits on top of the $0.75M–$2.25M baseline revenue BIEL is already modeling for early 2026 from active VA deployments, pilot clinics, and clinical onboarding.
De-Risked Growth: BIEL isn't paying for the retail marketing, distribution logistics, or shelf-space slotting fees—Electrome is. BIEL simply collects clean OEM hardware revenue on every single unit shipped.
Bottom Line: The revenue clock hasn't just started; it is accelerating. Late 2026 establishes the retail footprint, and 2027 is positioned to be a major breakout year for BIEL’s balance sheet.
2
